Items tagged with Drug-resistant TB
‘Worryingly high’ number of people infected with latent form of drug-resistant TB (post)
More than 19 million people around the globe are infected with one of the most complex forms of dormant tuberculosis, threatening efforts to control the fatal disease, researchers have warned.
Regional meeting on capacity building on DR-TB treatment in the EECA region (post)
The TB Europe Coalition organized a regional meeting on capacity building of civil society to advocate for safe and affordable drug-resistant TB (DR-TB) treatment in the region of Eastern Europe and Central Asia (EECA). The meeting took place on 18-20 June 2019 in Kiev, Ukraine.
Rifampin-resistant TB associated with HIV, increased mortality (post)
An analysis of 17 years of national surveillance data showed that all forms of rifampin resistance in patients with tuberculosis were positively associated with HIV infection, delayed culture conversion and increased mortality, researchers reported.
Mutations in TB bacteria make it resistant to drugs, say researchers (post)
-- Genetic variations identified in clinical strains from North India could be resistant to drugs
-- India accounts for 24% of global MDR-TB and 27% of global TB incidence among HIV-negative people
Janssen announces FDA accelerated approval for SIRTURO® as part of combination therapy to treat adolescents with pulmonary MDR-TB (post)
TITUSVILLE, NJ, August 9, 2019 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for SIRTURO® (bedaquiline) tablets as part of combination therapy in pediatric patients – those over the age of 12 and younger than 18 and weighing at least 66 pounds (30 kilograms) – with pulmonary multidrug-resistant tuberculosis (MDR-TB), when an effective treatment regimen cannot otherwise be provided. Approved under the FDA’s accelerated approval pathway based on time to sputum culture conversion, bedaquiline can now be used as part of combination therapy for eligible MDR-TB patients aged 12 years and over in the U.S. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
India must test new TB drug: Survivors appeal to Minister Harsh Vardhan (post)
Tuberculosis activists have appealed to Union Health Minister Dr Harsh Vardhan requesting India to test a new TB drug, which has been approved by the USFDA.
Why does TB find a 65-year-old drug so hard to resist? (post)
Since its discovery in 1954, there have been almost no recorded cases of tuberculosis becoming resistant to the antibiotic drug D-cycloserine (DCS) in patients. With resistance to many other drugs on the rise, a team of Crick researchers set out to find out why DCS has evaded resistance for so long.
Lancet Series: Tuberculosis 2019 (post)
Executive summary
Mylan working on launch of new TB drug in India (post)
Multinational pharmaceutical company Mylan is working with Drug Controller General of India (DCGI) to launch pretomanid, a medicine used to treat drug-resistant TB, said a company top-official.
Using whole-genome sequencing for early identification and containment of AMR pathogens (post)
Multiple factors aligned to establish sustained transmission of XDR-TB in KwaZulu-Natal, South Africa
Page 61 of 117 · Total posts: 0
←First 60 61 62 Last→